Protalix appoints Eliot Richard Forster as Chairman; Zeev Bronfeld retires

Protalix BioTherapeutics, Inc.

Forster appointed Chairman and independent director effective Sept 14, 2023; also joins Nominating Committee.
Zeev Bronfeld retires as Chairman after nearly three decades; cites recent drug approval as transition point.
Forster receives 10-year option for 85,715 shares vesting quarterly over 3 years and $70,000 annual fee.
Forster is non-executive chairman of Avacta Group and director of Immatics NV; former CEO of F-Star Therapeutics.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Zeev Bronfeld

Chairman of the Board

PLX · Protalix BioTherapeutics, Inc.

Effective: 2023-09-14
Successor: Eliot Richard Forster
Filed: September 12, 2023, 7:59 PM ET

Zeev Bronfeld, the Company’s current Chairman of the Board, has notified the Company of his retirement from the Company for personal reasons, effective as of the same date.

Appointed

Eliot Richard Forster

Chairman of the Board

PLX · Protalix BioTherapeutics, Inc.

Effective: 2023-09-14
Filed: September 12, 2023, 7:59 PM ET

On September 12, 2023, Protalix BioTherapeutics, Inc. (the “Company”) announced the appointment by its Board of Directors of Eliot Richard Forster, Ph.D. as Chairman of the Company’s Board of Directors effective as of September 14, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Zeev Bronfeld retired as Chairman of the Board at Protalix BioTherapeutics, Inc..

Action: retired
Role: Chairman of the Board

Exact text from the filing

Zeev Bronfeld, the Company’s current Chairman of the Board, has notified the Company of his retirement from the Company for personal reasons, effective as of the same date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eliot Richard Forster was appointed as Chairman of the Board at Protalix BioTherapeutics, Inc..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

On September 12, 2023, Protalix BioTherapeutics, Inc. (the “Company”) announced the appointment by its Board of Directors of Eliot Richard Forster, Ph.D. as Chairman of the Company’s Board of Directors effective as of September 14, 2023.

View on SEC.gov

Protalix BioTherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-015635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.